Skip to main content

Cash Raising

 In my experience, a cash raising exercise by a company puts downward pressure on the share price, and sometimes that is a long-term effect. The only people who want that are those who have already shorted that stock and those who want to buy shares at an even lower price.

However, sometimes it goes the other way.

Recently BOT did a cash raise for 13 cents a share when the share price was 15,5 cents. I (and others) certainly expected that the share price would drop to 12 or 13 cents. BUT...

The raise was over-subscribed; they wanted to raise $10,000,000 and got $13,500,000. This indicated that there are lots of high net worth investors who agree with the sentiment that I (and plenty of others) have been statin: the fundamentals of GOT are good and the company will go places during this (Australian) financial year.

The share price barely dropped before it started rising again.

There were those who were expecting the drop so they could buy in (or buy more) at a cheaper rate, and they expressed their disappointment.

BOT's long-term future looks exciting. June 2024 should see FDA approval for their sweat blocker that is already seling well in Japan. The revenue raised just last week will fund the manufacturing, marketing and distribution. The money raised from that will then be used to progress their other drugs that are even more exciting and hold even more promise.

I note that a lot of shareholders are now looking to a strong future for BOT. I have a different opinion.

Tthe future is strong, YES! But I don't think BOT will be there. I think a big pharma will pick this company up... buying the whole lot. Shareholders will receive a great windfall, but no long-term benefits, UNLESS the bigger company does a shares offer instead of a cash offer.

The reasoning behind this is BOT's sweat blocker looks to be "best on market" with zero side effects. It is already selling well in Japan and about to hit Korea. Once the FDA approves the drug (and the only objection they had was in the instructions - one missing word, one sentence needing to be in a bigger font, and the layout changed from portrait to landscape) the American market opens up with massive opportunities. 

And since BOT is cashed up, it should open up with a bang.

There will be plenty of people who look back and think "if only...", but that's the case a lot of the time. 

Personally, I am looking forward to what the next 6 months bring, it should be exciting.

Comments

Popular posts from this blog

A Couple of Updates

 Well, it's Monday morning and the week has started with a bang. First, PFE announced that there was an unexpected problem with their test drill and they have had to abandon that and go to a new test drill site. A delay, but no real issue apart from that. And the market hated that. Good news for those wanting to buy, not so good for existing holders. IMC released their AGM presentation which indicates that there will be some news in December and then a very busy (and hopefully productive) 2025. Sales are good and continuing to get better and better.

2025 - an early start

 Ok., so here we go on my Trump-era goal. Just bought MXR (yes, on the ASX). AAR wants to take them over at 7 cents as a scrip payment (paying in AAR shares instead of cash). The current share price is 6.3 cents. So that should be a quick 10% gain. However... this does look like a lowball offer and may yet be increased. MXR has great assets and AAR already owns almost 20% of MXR. So AAR is committed to a deal and that may just attract other attention. It looks like a no-brainer to start 2025. Yes, there is always some risk, but this one looks pretty good. I have done a bit more research and have some exciting thoughts, including one that looks a little like another WGO (which returned handsomely on a takeover). More news coming as I do more reseach.  Another one that looks good for a quick profit is GES, but as I write this, there are no shares at the right price (.05).

Out of 2

 I ahd some bills to pay and these 2 got the chop: PFE - such promise, such disappointmen IMC - I always had some ethical problems with this one.  But there it is. Bills paid, and a little left over to find something new with.